This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.

Unlock the details of this groundbreaking opportunity here...

Patrick Yang Biography and Net Worth

Director of Codexis

Before joining the Codexis board, Dr. Patrick Y. Yang served as executive vice president and global head of technical operations for Hoffmann-La Roche where he was responsible for Roche’s pharmaceutical and biotech manufacturing operations, process development, quality, regulatory and supply management functions. Before joining Roche upon its acquisition of Genentech, Yang worked as Genentech’s executive vice president of product operations and was a member of the company’s executive committee. He also held leadership roles at Merck, including vice president of Asia/Pacific manufacturing operations and vice president of supply chain management. Prior to Merck, Yang worked for General Electric in various leadership role in engineering, technology and manufacturing. Most recently, Yang worked as executive vice president of Juno Therapeutics in 2017-2019.

Yang currently serves on the board of directors of PharmaEssentia Corporation, Amyris, Inc., Acepodia, Inc., Taiwania Capital Management, and Sana Biotechnology. Yang earned his bachelor's in engineering from National Chiao Tung University in Taiwan, a master's degree in engineering from the University of Cincinnati, and a PhD in engineering from Ohio State University.

What is Patrick Y. Yang's net worth?: The estimated net worth of Patrick Y. Yang is at least $208,056.80 as of June 16th, 2021. Dr. Yang owns 78,512 shares of Codexis stock worth more than $208,057 as of April 25th. This net worth approximation does not reflect any other assets that Dr. Yang may own. Learn More about Patrick Y. Yang's net worth.
How do I contact Patrick Y. Yang?: The corporate mailing address for Dr. Yang and other Codexis executives is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. Codexis can also be reached via phone at (650) 421-8100 and via email at [email protected]. Learn More on Patrick Y. Yang's contact information.
Has Patrick Y. Yang been buying or selling shares of Codexis?: Patrick Y. Yang has not been actively trading shares of Codexis in the last ninety days. Most recently, Patrick Y. Yang sold 8,000 shares of the business's stock in a transaction on Monday, December 13th. The shares were sold at an average price of $31.60, for a transaction totalling $252,800.00. Learn More on Patrick Y. Yang's trading history.
Who are Codexis' active insiders?: Codexis' insider roster includes Byron Dorgan (Director), Bernard Kelley (Director), John Nicols (CEO), Dennis Wolf (Director), and Patrick Yang (Director). Learn More on Codexis' active insiders.
Are insiders buying or selling shares of Codexis?: In the last year, Codexis insiders bought shares 3 times. They purchased a total of 32,484 shares worth more than $55,402.80. In the last year, insiders at the biotechnology company sold shares 1 times. They sold a total of 20,000 shares worth more than $42,200.00. The most recent insider tranaction occured on November, 15th when Director Byron L Dorgan sold 20,000 shares worth more than $42,200.00. Insiders at Codexis own 6.3% of the company. Learn More about insider trades at Codexis.
Information on this page was last updated on 11/15/2023.

Patrick Y. Yang Insider Trading History at Codexis

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/13/2021	Sell	8,000	$31.60	$252,800.00
6/16/2021	Sell	20,000	$20.31	$406,200.00	78,512
4/6/2021	Sell	20,000	$24.71	$494,200.00
9/3/2019	Buy	6,000	$13.97	$83,820.00	76,764
8/30/2019	Buy	30,000	$8.74	$262,200.00	133,070
8/22/2019	Buy	12,000	$12.94	$155,280.00	70,764
12/20/2018	Sell	50,000	$18.52	$926,000.00	78,817
9/19/2018	Sell	50,000	$18.20	$910,000.00	128,817
8/16/2018	Sell	150,340	$14.45	$2,172,413.00	120,896
7/19/2018	Sell	50,000	$15.46	$773,000.00	329,157
8/21/2017	Buy	10,000	$3.98	$39,800.00	348,234
11/15/2016	Buy	10,000	$4.83	$48,300.00	320,340
9/11/2015	Buy	10,000	$3.47	$34,700.00	290,246
8/24/2015	Buy	10,000	$3.84	$38,400.00	280,246
8/14/2015	Buy	20,000	$3.97	$79,400.00
11/18/2014	Buy	20,000	$2.35	$47,000.00
11/17/2014	Buy	20,000	$2.34	$46,800.00
8/12/2014	Buy	60,000	$2.22	$133,200.00

Patrick Y. Yang Buying and Selling Activity at Codexis

Codexis Company Overview

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Today's Range

Now: $2.65

$2.64

$2.74

50 Day Range

MA: $3.31

$2.65

$4.65

2 Week Range

Now: $2.65

$1.45

$4.91

Volume

281,863 shs

Average Volume

554,682 shs

Market Capitalization

$186.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.01

Jim Cramer’s “The Biggest Drug Ever”

From Behind the Markets | Ad